SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 20.97 |
| Enterprise Value ($M) | 16.61 |
| Book Value ($M) | 3.41 |
| Book Value / Share | 2.28 |
| Price / Book | 6.15 |
| NCAV ($M) | 3.41 |
| NCAV / Share | 2.28 |
| Price / NCAV | 6.16 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -2.23 |
| Return on Assets (ROA) | -0.82 |
| Return on Equity (ROE) | -0.87 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 3.69 |
| Current Ratio | 3.69 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 4.67 |
| Assets | 4.68 |
| Liabilities | 1.27 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.00 |
| Operating Income | 0.00 |
| Net Income | 0.00 |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | 0.00 |
| Cash from Investing | 0.00 |
| Cash from Financing | 0.00 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G/A | Armistice Capital, Llc | 4.99 | -94.38 | |
| 13G | Havlickova 648 a.s. | 6.20 | ||
| 13G/A | Murphy John Raymond | 5.49 | 20.18 | |
| 13G | Pham Quang X | 48.57 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 28,782 | 111,226 | 25.88 | |
| 6,834 | 33,915 | 20.15 | |
| 16,567 | 52,618 | 31.49 | |
| 12,007 | 39,447 | 30.44 | |
| 7,614 | 48,537 | 15.69 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| CSCI – COSCIENS Biopharma Inc. | CTXR – Citius Pharmaceuticals, Inc. |
| CUE – Cue Biopharma, Inc. | CYCC – Cyclacel Pharmaceuticals, Inc. |
| CYCN – Cyclerion Therapeutics, Inc. |
Financial data and stock pages provided by
Fintel.io